4 recruiting, 3 not yet recruiting, 2 completed, 2 unknown. 13 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 4, Not yet recruiting 3, Completed 2, Unknown 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Urinary Bladder Cancer: new trials by email Literature Review of Urinary Bladder Cancer trials Research Report on Urinary Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TR115 in ARID1A-Mutated Advanced Solid Tumors TR115 - Ovarian Clear Cell Carcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Tarapeutics Science Inc. | 50 | 2026-09-20 | 2026-08-28 |
| Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma Trastuzumab Rezetecan plus Camrelizumab - Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Sheng Tai | 44 | 2026-06-05 | 2026-06-10 |
| SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel) - Urinary Bladder Cancer, Upper Tract Urothelial Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 28 | 2026-03-06 | 2026-05-06 |
| Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer Gemcitabine and Cisplatin (DD GC) - Urinary Bladder Cancer | Phase 2 | Not yet recruiting | Assiut University | 30 | 2025-09-01 | 2025-09-19 |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Riluzole, Placebo - Breast Cancer, Sarcoma | Phase 2 | Recruiting | University of California, Irvine | 75 | 2024-12-02 | 2026-07-14 |
| Intravesical Gem/Doce in Patients With NMIBC gemcitabine + docetaxel - Urinary Bladder Cancer | Phase 2 | Active not recruiting | University of Arizona | 31 | 2023-03-01 | 2026-10-26 |
| Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer Pembrolizumab - Bladder Cancer, Bladder Neoplasms | Phase 2 | Recruiting | Peking University First Hospital | 54 | 2021-12-07 | 2022-01-10 |
| Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin - Urinary Bladder Cancer | Phase 2 | Recruiting | Zhujiang Hospital | 41 | 2021-06-03 | 2026-10-09 |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care - Bladder Cancer, Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 36 | 2019-04-02 | 2023-08-14 |
| Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder Nivolumab, Radiation therapy of the pelvis, Radical cystectomy with standardized pelvic lymphadenectomy - Urinary Bladder Cancer | Phase 2 | Unknown | Technical University of Munich | 33 | 2019-02-04 | 2022-10-20 |
| A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study nivolumab 480mg, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg - Urinary Bladder Cancer, Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2019-01-07 | 2022-08-12 |
| PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer GemCis + Panitumumab, GemCis - Urinary Bladder Cancer | Phase 2 | Terminated | WiSP Wissenschaftlicher Service Pharma GmbH | 2 | 2010-07-01 | 2015-06-03 |
| Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ Vicinium - Urinary Bladder Cancer, Bladder Cancer | Phase 2 | Completed | Sesen Bio, Inc. | 46 | 2007-03-01 | 2020-05-12 |
Urinary Bladder Neoplasms (13) · Urogenital Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hodgkin Disease (1) · Kidney Neoplasms (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Male Urogenital Diseases (13) · Neoplasms (13) · Neoplasms by Site (13) · Urinary Bladder Diseases (13) · Urogenital Diseases (13) · Urologic Diseases (13) · Urologic Neoplasms (12) · Urogenital Neoplasms (11) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms by Histologic Type (2) · Adnexal Diseases (1)
Gemcitabine (4) · Cisplatin (2) · Docetaxel (2) · Nivolumab (2) · Administration, Intravesical (1) · Capecitabine (1) · Cystectomy (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Mitomycin (1) · Neoadjuvant Therapy (1) · Panitumumab (1) · Riluzole (1) · VB4-845 (1) · camrelizumab (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Assiut University (1) · NanOlogy, LLC (1) · Peking University First Hospital (1) · Rutgers, The State University of New Jersey (1) · Sesen Bio, Inc. (1) · Sheng Tai (1) · Tarapeutics Science Inc. (1) · Technical University of Munich (1) · University of Arizona (1) · University of California, Irvine (1) · WiSP Wissenschaftlicher Service Pharma GmbH (1) · Zhujiang Hospital (1)
United States (5) · China (3) · Germany (2) · Canada (1) · Egypt (1) · Netherlands (1)
Abai Xu, doctor (1) · Adriaan D. Bins, MD PhD (1) · Alexandre Chan, PharmD, MPH (1) · Amal Rayan, Professor (1) · Donald Lamm, MD, FACS (1) · Hanjiang Xu (1) · Juan Chipollini, MD (1) · Kurt Miller, Prof. Dr. (1) · Sebastian C Schmid, PD Dr. med (1) · Sheng Tai (1) · Wendy Chapman (1) · Zhi-Song He, MD (1)
2009 (1)